7 Best Peptides for Body Composition

What to Know Before Choosing a Peptide for Body Composition

Body composition is one of the most searched goals in the peptide space, and the field of compounds people use for it is genuinely wide. It spans GLP-1 agonists prescribed through telemedicine, growth hormone secretagogues sold as research chemicals, and recovery peptides used to support training volume over time. A compound earned a slot on this list because people use it or are actively discussing using it for this goal. FDA approval, randomized trial data, and regulatory status were not the filters. What matters is honest inclusion and honest evidence: every compound here is described with the clearest picture of what the research actually shows, including where that picture is thin or entirely preclinical.

The evidence landscape for body composition peptides is unusually uneven. Some of these compounds have been through the largest obesity outcome trials ever conducted. Others rest almost entirely on animal models or community-reported experience, with no published human data for this specific use. That spread is real, and this article names it plainly for each compound rather than smoothing it over or quietly dropping the harder-to-defend options.

These compounds are numbered by how prominently they appear in research and in real-world use, not as a recommendation of one over another. Number one is not the best peptide for your goals. It is the one with the deepest footprint across the published literature and the documented user base. The right compound for any individual depends on whether fat loss, muscle gain, or recomposition is the primary target, what else is being used, and what a qualified clinician recommends. That personalized decision is what the MyPeptidePal app is built for.

1. Semaglutide: For Fat Loss Through Appetite Suppression

Semaglutide is a glucagon-like peptide-1 receptor agonist, which means it binds to receptors in the hypothalamus, the brain's appetite-control center, and increases satiety signals while reducing what users commonly describe as food noise, the near-constant mental pull toward eating. It also slows gastric emptying, so food stays in the stomach longer, which prolongs fullness and blunts post-meal blood glucose spikes.

It is FDA-approved for type 2 diabetes management and for chronic weight management in adults with a body mass index at or above 30, and it is widely available through telemedicine platforms that provide a qualifying medical evaluation. The trial data behind semaglutide sits at the top of what exists for any weight-management compound. It has been evaluated in some of the largest obesity outcome trials ever conducted, with results showing significant reductions in fat mass across diverse populations.

The honest consideration for body composition specifically is that semaglutide drives weight loss primarily through appetite suppression and caloric reduction. It does not directly stimulate muscle protein synthesis. Without adequate protein intake and resistance training alongside it, the weight lost can include a meaningful proportion of lean mass, which can actually raise body fat percentage even as the scale drops. Community reports consistently reflect this: users who pair semaglutide with structured training and high protein intake report substantially better composition outcomes than those who use appetite suppression alone. It is a powerful tool for the fat-loss side of body composition, and it works best as part of a structured approach rather than as a standalone solution.

2. Tirzepatide: For Fat Loss With Improved Metabolic Partitioning

Tirzepatide adds a second mechanism to the GLP-1 framework. It agonizes both the GLP-1 receptor and the GIP receptor, where GIP stands for glucose-dependent insulinotropic polypeptide, a hormone that enhances insulin sensitivity and influences how the body routes incoming nutrients. By working both pathways simultaneously, tirzepatide improves the metabolic environment in ways that appear to favor fat storage reduction over lean tissue loss, beyond what appetite suppression alone produces.

The clinical trial data is among the strongest in the weight-loss field. In a large randomized controlled trial, 97 percent of participants lost at least five percent of body weight over 72 weeks, with average reductions substantially larger than that in the higher-dose arms. It is FDA-approved for type 2 diabetes under one brand name and for chronic weight management under another, with the weight-management approval granted in 2023.

In community discussions, tirzepatide has become one of the most frequently mentioned compounds for significant fat loss over the past two years. Users report losing substantial amounts of weight over six to twelve months, often noting that appetite suppression felt more graduated and manageable than with earlier GLP-1 options. The same consideration applies as with semaglutide: the mechanism is primarily metabolic and appetite-based, so resistance training and protein intake remain essential for preserving lean mass while fat comes off. For someone whose primary body composition goal is significant fat reduction with metabolic support, tirzepatide currently represents the most evidence-backed option available.

3. Tesamorelin: For Visceral Fat Reduction and Lean Mass Support

Tesamorelin is a growth hormone-releasing factor analog, meaning it signals the pituitary gland to produce more growth hormone rather than supplying growth hormone directly. That distinction matters: the pituitary still controls the pulse, the timing, and the amplitude, so the endocrine response stays within a more physiological range than exogenous growth hormone administration. The growth hormone released then stimulates the liver to produce insulin-like growth factor 1, which supports muscle protein synthesis alongside the fat-metabolism effects.

It is the only peptide FDA-approved specifically for the reduction of excess fat, though that approval is specific to abdominal fat accumulation in a defined medical context. Off-label, it is prescribed by physicians and available through compounding pharmacies with appropriate oversight for individuals pursuing visceral fat reduction and lean mass improvement more broadly. Controlled clinical trials of approximately 26 weeks have shown significantly reduced visceral fat and increased lean body mass in study populations. Visceral fat, the deep abdominal fat surrounding the organs, is the specific target, making tesamorelin the most clinically grounded option for that particular body composition concern.

Access requires physician oversight, and in the United States that typically means a 503A compounding pharmacy rather than a standard retail chain. Lab monitoring is part of any responsible protocol. For someone whose body composition concern centers specifically on visceral fat and who has access to appropriate clinical supervision, tesamorelin is the most directly studied tool available.

4. CJC-1295 and Ipamorelin: For Growth Hormone-Driven Recomposition

CJC-1295 and Ipamorelin are almost always discussed together because they work as a complementary pair. CJC-1295 is a growth hormone-releasing hormone analog that stimulates the pituitary over an extended window. Ipamorelin is a ghrelin receptor agonist, meaning it mimics ghrelin, the hormone that triggers growth hormone release, and does so in a way that produces clean, pulsatile growth hormone spikes without the significant cortisol or prolactin elevation associated with older growth hormone-releasing peptides. Together, the two compounds stimulate the growth hormone axis from two different angles simultaneously, which produces a more robust GH pulse than either achieves alone.

Neither compound is FDA-approved for body composition use. Both are classified as research chemicals and are not legally available for human use outside of clinical research settings. That is the accurate regulatory picture. The human evidence base is real but limited: endocrine studies have confirmed that compounds in this class raise growth hormone and insulin-like growth factor 1 levels in humans, which is the proposed mechanism for body composition effects. Large randomized controlled trials examining muscle gain or fat loss in healthy adults do not exist for this combination.

Across fitness-focused community platforms and protocol discussions, this pair is among the most consistently referenced combinations for overall recomposition: more lean mass, less fat, improved sleep quality, and better recovery alongside training. Users commonly report effects that feel more gradual and cleaner in terms of side effects compared to exogenous growth hormone. The evidence is a mix of endocrine pharmacokinetics in humans and a substantial body of user-reported experience, rather than the outcome trial data that exists for GLP-1 agonists. That distinction matters when evaluating whether this combination fits a given goal.

5. Sermorelin: For Moderate Growth Hormone Stimulation

Sermorelin is a growth hormone-releasing hormone, specifically the shortest biologically active fragment of the naturally occurring GHRH molecule. It stimulates the pituitary to release growth hormone through the same mechanism as endogenous GHRH, which means it is subject to the same natural negative feedback controls that prevent runaway GH elevation. That built-in ceiling is often cited as a distinguishing feature relative to longer-acting secretagogues.

It was historically FDA-approved for a specific diagnostic purpose related to growth hormone secretion testing, and it has been prescribed off-label by physicians and through telemedicine clinics for anti-aging and body composition purposes for years. It is not FDA-approved for general fat loss or muscle gain. Access typically requires compounding pharmacy involvement and physician oversight with relevant lab monitoring. The human evidence for body composition effects in older adults with growth hormone insufficiency is moderate: randomized trials in that population have shown meaningful improvements in lean mass, reductions in body fat percentage, and increases in insulin-like growth factor 1. The data in healthy, younger, or well-trained individuals is considerably thinner.

In practice, sermorelin occupies a similar space to the CJC-1295 and ipamorelin combination but with a milder and shorter-acting growth hormone stimulus. It is frequently included in stacking protocols alongside those two compounds. For someone pursuing growth hormone support with physician oversight and who prefers an option that sits in a clearer regulatory space than pure research chemicals, sermorelin is the most accessible entry point into this compound class.

6. AOD-9604: For Targeted Fat Metabolism Without Growth Effects

AOD-9604 is a modified fragment derived from the structure of human growth hormone, specifically the region associated with fat metabolism, with modifications designed to remove the growth-stimulating and blood-sugar-affecting properties of the parent molecule. In animal studies, it has been shown to stimulate the breakdown of stored fat, a process called lipolysis, and to inhibit the formation of new fat cells, a process called lipogenesis, without raising insulin-like growth factor 1 or affecting glucose metabolism.

That selective action is the core of its appeal in body composition discussions. For someone who wants fat-metabolism signaling associated with growth hormone-related compounds but without hormonal disruption, growth promotion, or blood sugar effects, AOD-9604 is the compound that appears most purpose-built for that use case. It is research-only with no FDA approval for human use. The evidence base is primarily preclinical, with the most meaningful mechanistic data coming from animal models. Human trial data specific to fat loss as a body composition outcome is limited and has not produced the kind of robust efficacy picture that the GLP-1 compounds have.

Community use is real and steady: AOD-9604 appears consistently in body composition discussions, particularly among people who want to layer a fat-targeted compound onto a protocol that already includes other agents. The evidence here is primarily from animal research and experiential reports from community protocols, rather than from controlled human outcome trials. Naming that plainly is part of what makes this list useful.

7. BPC-157: For Recovery Support During Intensive Training

BPC-157, short for body protection compound 157, is a synthetic peptide that does not fit neatly into either the fat-loss or muscle-growth categories. Its mechanism centers on angiogenesis, the formation of new blood vessels that deliver nutrients and oxygen to tissues, along with inflammation reduction and promotion of tissue repair. People use it in body composition contexts primarily as a recovery tool: the logic is that faster recovery from training stress allows more sustained training volume over time, which indirectly supports both fat loss and muscle gain.

The regulatory picture here matters and should be stated directly. BPC-157 is not FDA-approved and is classified as a research chemical. The FDA has specifically flagged it as a compound for which compounded forms may present significant safety risks, including immunogenicity, meaning the potential for an adverse immune response to the compound itself. The USADA has stated that there is insufficient human study data to establish a safe dose. The evidence for body composition effects is essentially extrapolated from rodent models; no published human clinical trial has examined BPC-157 for fat loss or muscle gain as of 2026.

Despite that thin evidence base and real regulatory caution, BPC-157 appears consistently in community discussions about training recovery. Users report clearing nagging injuries, reducing joint and tendon pain, and returning to full training capacity sooner than expected. Those reports are user-reported and uncontrolled, not clinical findings. The compound belongs on this list because people actively use and discuss it in body composition contexts, and honest inclusion means naming it alongside a direct statement of where its evidence stands. Anyone considering it should weigh the FDA's specific concerns and the absence of human safety and efficacy data seriously.

How These Peptides Compare

Frequently Asked Questions

Are these peptides legal to buy and use?

It depends entirely on the compound. Semaglutide and tirzepatide are FDA-approved medications available by prescription through qualifying telemedicine or in-person medical visits. Tesamorelin and sermorelin also require prescriptions and typically involve compounding pharmacies. CJC-1295, ipamorelin, AOD-9604, and BPC-157 are classified as research chemicals in the United States, meaning they are not approved for human use and are not legally sold for that purpose, though they are widely available through unregulated channels. Growth hormone secretagogues are also banned by the World Anti-Doping Agency, so competitive athletes should factor that into any consideration of compounds in that class.

Do these peptides work without diet and training?

No, not in any meaningful body composition sense. GLP-1 agonists drive caloric reduction through appetite suppression, so the fat loss they produce is still fundamentally about energy intake and how the body responds to it. Without adequate protein and resistance training, a significant portion of the weight lost can come from lean mass rather than fat, worsening body composition even as the scale drops. Growth hormone secretagogues operate on anabolic and metabolic pathways that require a training stimulus to translate into meaningful lean mass changes. Every compound on this list works within a physiology that still responds to caloric balance, protein intake, and the mechanical stimulus of exercise.

How is tirzepatide different from semaglutide for body composition?

Both suppress appetite through GLP-1 receptor agonism and carry strong clinical trial data for fat loss. Tirzepatide adds a second mechanism through the GIP receptor, which appears to improve insulin sensitivity and influence how the body partitions nutrients between fat storage and other metabolic uses. In clinical trials, tirzepatide has generally shown larger average fat loss than semaglutide at comparable timeframes, though both produce meaningful results. Neither compound directly builds muscle; the meaningful difference between them is the depth and breadth of metabolic effects rather than a fundamentally different mechanism of action.

What is the difference between a GLP-1 agonist and a growth hormone secretagogue?

GLP-1 agonists work primarily through appetite and metabolism: they reduce how much you want to eat, slow digestion, and improve the hormonal environment around fat storage and nutrient use. Growth hormone secretagogues work primarily by stimulating the pituitary gland to release more growth hormone, which then drives insulin-like growth factor 1 production and anabolic signaling in muscle tissue. The two classes address body composition from different directions, and they are sometimes used together under clinical supervision for people pursuing simultaneous fat loss and lean mass support.

Is BPC-157 worth considering for body composition goals?

BPC-157 does not directly drive fat loss or muscle gain. Its proposed role in body composition protocols is as a recovery accelerator: faster resolution of training-related injury, reduced joint and tendon pain, and the ability to sustain higher training volumes over time. Community reports along these lines are consistent. What is equally consistent is that no human clinical trial has established efficacy or safety for BPC-157 in any body composition context as of 2026, and the FDA has specifically flagged compounded forms as presenting potential safety risks. For someone whose primary goal is improving body composition metrics, BPC-157 would not be a lead compound; it is used as a supporting tool by people already running other protocols who want to minimize training downtime.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for body composition in one place.